Key Developments: Abaxis Inc (ABAX.OQ)

ABAX.OQ on NASDAQ Stock Exchange Global Select Market

58.48USD
24 Dec 2014
Price Change (% chg)

$0.22 (+0.38%)
Prev Close
$58.26
Open
$58.26
Day's High
$59.05
Day's Low
$58.06
Volume
29,483
Avg. Vol
70,711
52-wk High
$60.91
52-wk Low
$33.62

Search Stocks

Latest Key Developments (Source: Significant Developments)

Abaxis Inc acquires UK-based distribution organization
Friday, 21 Nov 2014 08:00am EST 

Abaxis Inc:Says completion of stock purchase agreement to acquire 100 pct of QCR & Trio Diagnostics Limited, a United Kingdom based distribution organization.The transaction closed on Nov. 17.  Full Article

Abaxis Inc declares cash dividend
Thursday, 23 Oct 2014 08:00am EDT 

Abaxis Inc:Declares cash dividend of $0.10 per common share.Dividend will be payable on Dec. 16.Record at the close of business on Nov. 17.  Full Article

Abaxis Inc announces distribution agreement with Henry Schein Animal Health
Tuesday, 21 Oct 2014 07:00am EDT 

Abaxis Inc:Has entered into a definitive non-exclusive distribution agreement with Henry Schein Animal Health.Henry Schein will sell the full line of Abaxis veterinary products throughout the United States with sales and marketing activities commencing immediately.  Full Article

Patterson Companies Inc announces strategic partnership with Abaxis Inc
Wednesday, 1 Oct 2014 08:30am EDT 

Patterson Companies Inc:Announces a new strategic partnership with Abaxis Inc.Under the terms of the agreement, Patterson will sell the full line of Abaxis veterinary diagnostic products, including external reference lab services (Abaxis Veterinary Reference Laboratories) and in-clinic testing.  Full Article

Abaxis Inc declares quarterly dividend
Thursday, 24 Jul 2014 04:01pm EDT 

Abaxis Inc:Declares a quarterly dividend of $0.10 per common share to be paid on Sept. 17, to all shareholders of record as of the close of business on Sept. 3.  Full Article

Abaxis Inc announces USDA approval of VetScan Canine Ehrlichia Antibody Test Kit
Tuesday, 1 Jul 2014 08:00am EDT 

Abaxis Inc:Says Center for Veterinary Biologicals of the U.S. Department of Agriculture (USDA) has approved its VetScan Canine Ehrlichia Antibody Test Kit for use in rapid detection of canine Ehrlichia.Each test can be purchased on an individual basis so that each practitioner has the flexibility to decide which tests to use based on such factors as history and presentation of patient as well as incidence of particular disease in his or her geographic area.  Full Article

Abaxis Inc and VCA Antech Inc announces long term product supply agreement and co marketing agreement
Monday, 12 May 2014 06:30pm EDT 

Abaxis Inc and VCA Antech Inc:Says that they have entered into two long term agreements.The first a long-term product supply agreement for VCA's Animal Hospitals.The second a co-marketing agreement with VCA's Antech Diagnostic reference laboratories.Under the long term product supply agreement VCA will purchase VetScan VS2 chemistry analyzers and diagnostic reagent discs from Abaxis for placement in the majority of VCA's more than 600 animal hospitals located in North America.Additionally, VCA and Abaxis have entered into a non-exclusive co-marketing relationship to capitalize on new growth opportunities within the animal healthcare industry.  Full Article

Abaxis Inc declares quarterly cash dividend
Thursday, 24 Apr 2014 04:00pm EDT 

Abaxis Inc:Declares a quarterly dividend of $0.10 per common share.Payable on June 17, to all shareholders of record as of the close of business on June 3.  Full Article

Abaxis Inc receives health Canada class III approval for Piccolo Xpress
Tuesday, 8 Apr 2014 08:00am EDT 

Abaxis Inc:Health Canada approved Piccolo Xpress and Piccolo Reagent Discs as Class III medical device for use throughout Canada.  Full Article

Abaxis Inc And LamdaGen Corporation Enters Into R&D Diagnostic Collaboration
Friday, 25 Oct 2013 08:00am EDT 

Abaxis Inc and privately-held LamdaGen Corporation announced an R&D agreement to integrate LamdaGen's high-sensitivity Plasmonic ELISA technology on the Abaxis Piccolo and VetScan rotors. System feasibility testing is underway. LamdaGen's patented biosensor platform is based upon LSPR (Localized Surface Plasmon Resonance) and provides rapid, quantitative diagnostic results with broad dynamic range and detection levels in the femtomolar range.  Full Article

Search Stocks